Home › NDC Lookup › RxCUI directory › RxCUI 2055911

Eravacycline 50 MG Injection — RxCUI 2055911

Name: Eravacycline 50 MG Injection (RxCUI 2055911)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2055911 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2055911

Official nameEravacycline 50 MG Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known aseravacycline 50 MG (equivalent to eravacycline dihydrochloride 63.5 MG) Injection

FDA products mapped2

Package NDCs mapped3

Reported Medicaid activity (SDUD)277 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Eravacycline Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Xerava is an antibiotic used to treat serious bacterial infections inside the abdomen — things like an infected appendix, perforated bowel, or other complicated abdominal infection...
Xerava is given as an IV infusion — a slow drip into a vein — over about 60 minutes, usually every 12 hours. Your treatment will typically last somewhere between 4 and 14 days, dep...
How is Xerava given, and how long will I need it?
The most common side effects are nausea, vomiting, and reactions at the IV site like pain or redness. These are usually manageable. The more important things to watch for are signs...

📖 Read our full Eravacycline Injection guide →

🕸️ Concept Web — How Eravacycline 50 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Eravacycline 50 MG Injection RxCUI 2055911 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Eravacycline 2055906 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Xerava 2055912 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Eravacycline Injection 2055910 SCDF
- Eravacycline Injectable Product 2055909 SCDG
- Eravacycline Injection [Xerava] 2055914 SBDF
- Xerava Injectable Product 2055915 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Eravacycline 50 MG 2055908 SCDC
- Eravacycline 50 MG Injection [Xerava] 2055916 SBD
- Eravacycline 50 MG [Xerava] 2055913 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Eravacycline 50 MG SCDC · 2055908
Eravacycline Injection SCDF · 2055910
Eravacycline Injectable Product SCDG · 2055909

Brand-Name Concepts

Eravacycline 50 MG Injection [Xerava] SBD · 2055916
Eravacycline 50 MG [Xerava] SBDC · 2055913
Eravacycline Injection [Xerava] SBDF · 2055914
Xerava Injectable Product SBDG · 2055915
Xerava BN · 2055912

📦 FDA Products & Package NDCs

2 products · 3 package NDCs

3 package NDCs map to RxCUI 2055911 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
71773-0050-05	1 VIAL, GLASS in 1 CARTON (71773-050-05) / 1 INJECTION, POW...	Xerava	Tetraphase Pharmaceuticals, Inc.	2018-09-10
71773-0050-12	12 VIAL, GLASS in 1 CARTON (71773-050-12) / 1 INJECTION, PO...	Xerava	Tetraphase Pharmaceuticals, Inc.	2018-09-10
71773-0100-12	12 CARTON in 1 PACKAGE (71773-100-12) / 1 VIAL, GLASS in 1...	Xerava	Tetraphase Pharmaceuticals, Inc.	2020-09-14

Observed labelers: Tetraphase Pharmaceuticals, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J0122	Inj., eravacycline, 1 mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.